Dofetilide: Electrophysiologic Effect, Efficacy, and Safety in Patients with Cardiac Arrhythmias
Fatemah Shenasa1, Mohammad Shenasa1
1Heart and Rhythm Medical Group, Department of Cardiovascular Services, O'Connor Hospital, 105 North Bascom Avenue, San Jose, CA 95128, USA.
Insights
Dofetilide, a Class III antiarrhythmic, effectively treats arrhythmias by blocking potassium current (IKr). While safe for heart failure patients, it carries a risk of ventricular arrhythmias and requires dose adjustment for kidney impairment.
Area of Science:
- Pharmacology
- Cardiology
Background:
- Dofetilide is a Class III antiarrhythmic drug.
- It selectively blocks the rapid component of the delayed rectifier potassium current (IKr).
Purpose of the Study:
- To summarize the safety and efficacy of dofetilide.
- To highlight key considerations for its clinical use.
Main Methods:
- Review of existing clinical data and pharmacological properties of dofetilide.
Main Results:
- Dofetilide demonstrates safety in patients post-myocardial infarction and with heart failure.
- A significant adverse effect is the proarrhythmic risk, particularly torsades de pointes.
- Renal excretion is approximately 80%, necessitating dose adjustment in renal impairment.
- Administration is contraindicated if QTc exceeds 500 ms.
Conclusions:
- Dofetilide is a valuable antiarrhythmic agent with specific safety considerations.
- Careful patient selection and monitoring are crucial for managing proarrhythmic risks and renal function.
- Strict adherence to QTc interval guidelines is essential.
Abstract:
Dofetilide is a class III antiarrhythmic agent with a selective blockade of rapid component of delayed rectifier potassium current (IKr). Dofetilide was found to be safe in patients after myocardial infarction and those with congestive heart failure and left ventricular systolic dysfunction (ejection fraction of less than 35%). An important adverse effect of dofetilide is its potential proarrhythmic risk of ventricular tachyarrhythmias, mostly torsades de pointes. Because dofetilide has about an 80% renal excretion, dose adjustment is required in patients with impaired renal function. Dofetilide should not be given or discontinued if the QTc is greater than 500 ms.
More Related Videos
10:01High-Throughput Optical Controlling and Recording Calcium Signal in iPSC-Derived Cardiomyocytes for Toxicity Testing and Phenotypic Drug Screening
Published on: March 31, 2022
09:35Preclinical Cardiac Electrophysiology Assessment by Dual Voltage and Calcium Optical Mapping of Human Organotypic Cardiac Slices
Published on: June 16, 2020
Related Concept Videos
Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers
Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...
Antiarrhythmic Drugs: Class IV Agents as Calcium Channel Blockers
Verapamil, a calcium channel blocker, inhibits calcium movement across myocardial cell membranes and vascular smooth muscle. This results in the dilation of coronary and...
Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers
Dysrhythmias IV: Characteristics of Bradyarrhythmias
ECG Interpretation of Arrhythmias II: Atrial, Junctional and Ventricular Arrhythmias
